Balyasny Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Balyasny Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750,000	Closed	-$51.1M	–	3573
2022 Q3	$51.1M	Buy	+750,000	New	+$41.4M	0.16%	148
2019 Q2	–	Sell	-315,000	Closed	-$16.7M	–	1806
2019 Q1	$16.7M	Buy	315,000 +135,000	+75%	+$6.63M	0.11%	265
2018 Q4	$7.39M	Buy	180,000 +142,000	+374%	+$5.32M	0.05%	420
2018 Q3	$1.55M	Sell	38,000 -5,000	-12%	-$221K	0.01%	1063
2018 Q2	$1.94M	Sell	43,000 -82,000	-66%	-$3.73M	0.01%	938
2018 Q1	$6.04M	Buy	+125,000	New	+$6.97M	0.03%	658

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's GBT Position: Q4 2022 in Review

Balyasny Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,151,518 shares — an estimated $78.4M sold.

Balyasny Asset Management first reported a position in GBT in Q1 2016 and held it in 9 quarters. The position peaked at $78.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Balyasny Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Balyasny Asset Management sold 1,151,518 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $78.4M.
Balyasny Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 9 quarters.
Balyasny Asset Management's Global Blood Therapeutics, Inc. position peaked at $78.4M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.